leisure time -WSS

leisure time

author：comprehensive 2025-10-01 11:46:18 - browse：7

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Readout LOUD podcast: ESMO highlights & Roivant's big deal

focus

WSS

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Congress must give Medicare recipients genetic counseling access

Trump cancels press conference intended to dispute Georgia election interference charges

Majority of Americans think Trump's Ga. election interference case is serious: POLL

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Humans aren't the only ones with an imagination. Rats have it too

explore

leisure time

entertainment

Continuity nursing helped my family in our darkest PICU moments

New definition of a human embryo proposed amid rapid advances

Hollywood unions extend contract negotiations for actors

ActiGraph execs on goal of drug approvals with digital endpoints

After affirmative action ruling, medical educators look to 'holistic review'

Prime Medicine says its gene editing passes test in monkeys

Heart attack and stroke risk calculators need revising

After Sarepta trial failure, Duchenne families brace for more debate

As demand for Covid shots wanes, Moderna seeks its next success

After Sarepta trial failure, Duchenne families brace for more debate

entertainment

New details revealed about Purdue's marketing of OxyContin

Evacuations in place as 3 wildfires burn in eastern Washington state

Baltimore teen accused of firing into crowd during block party mass shooting

How to convince healthy people to buy insurance

Hilary may become 1st tropical storm to make landfall in California in 84 years

Listen: Racing for gene therapy & a pioneering approval

focus

knowledge

hotspot

hotspot